

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/44	A1	(11) International Publication Number: WO 98/37887 (43) International Publication Date: 3 September 1998 (03.09.98)
(21) International Application Number: PCT/JP98/00776 (22) International Filing Date: 26 February 1998 (26.02.98) (30) Priority Data: 9/60083 28 February 1997 (28.02.97) JP (71) Applicant (for all designated States except US): ISHIHARA SANGYO KAISHA LTD. [JP/JP]; 3-15, Edobori 1-chome, Nishi-ku, Osaka-shi, Osaka 550-0002 (JP). (72) Inventor; and (75) Inventor/Applicant (for US only): OGURA, Yoshifumi [JP/JP]; 787-32, Shibumi-cho, Tsu-shi, Mie 514-0063 (JP). (74) Agents: OGAWA, Toshiharu et al.; Torimoto Kogyo Building, 38, Kanda-Higashimatsushitacho, Chiyoda-ku, Tokyo 101-0042 (JP).		(81) Designated States: AU, CA, CN, IL, KR, NZ, RU, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ANTICANCER COMPOSITION COMPRISING A DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVE (57) Abstract <p>An anticancer composition comprising a diaminotrifluoromethylpyridine derivative of formula (I) or its pharmaceutically acceptable salt, as an active ingredient, wherein X is a cycloalkylcarbonyl group, a furan carbonyl group or a benzoyl group which may be substituted by a halogen atom, and Y is an alkylsulfonyl group.</p> <div data-bbox="1023 1134 1380 1260"><p style="text-align: right;">(I)</p></div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTION

ANTICANCER COMPOSITION COMPRISING A DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVE

TECHNICAL FIELD

5 The present invention relates to an anticancer composition comprising a diaminotrifluoromethylpyridine derivative or its pharmaceutically acceptable salt, as an active ingredient.

BACKGROUND ART

10 EP0465913-A discloses that a diaminotrifluoromethylpyridine derivative or its salt has a phospholipase A₂ inhibition activity and thus is useful as an active ingredient of an anti-inflammatory agent or an anti-pancreatitis agent. Further, the same

15 publication discloses that in platelets or cells related to inflammatory symptoms, phospholipase A₂ is secreted or activated by various stimulations and contributes to the production of a platelet activating factor (PAF) or some arachidonic acid methabolites, and that the arachidonic

20 acid methabolites have been found to be closely related to various diseases, for example, inflammatory symptoms such as rheumatoid arthritis, arthritis deformans, tenontitis, psoriasis and related dermatitis; nasal and bronchial airway troubles such as allergic rhinitis and

25 allergic bronchial asthma; and immediate hypersensitive reactions such as allergic conjunctivitis. On the other hand, it is disclosed that phospholipase A₂ secreted from

pancreas is activated in the intestine and exhibits a digestive action, but once activated in the pancreas, it is believed to be one of the factors causing pancreatitis. And, it is disclosed that the above

5 diaminotrifluoromethylpyridine derivative or its salt inhibits phospholipase A₂ and thus is effective for the treatment of the above-mentioned diseases caused by phospholipase A₂ such as inflammatory symptoms, nasal and bronchial airway troubles, immediate hypersensitive

10 reactions or pancreatitis. Thus, it is disclosed to be useful as an anti-inflammatory agent, an agent for treating bronchial asthma, an anti-allergy agent, an anti-pancreatitis agent, anti-nephritis agent, or anti-MOF (Multiple Organ Failure).

15 DISCLOSURE OF THE INVENTION

It is an object of the present invention to provide an anticancer composition comprising a diaminotrifluoromethylpyridine derivative or its pharmaceutically acceptable salt, as an active


20 ingredient.

The present inventors have conducted various studies on the pharmacological activities of the diaminotrifluoromethylpyridine derivative or its salt. As a result, they have found that such a compound has a

25 suppressive effect of carcinogenesis useful as an anticancer agent. The present invention has been accomplished on the basis of this discovery.

That is, the present invention provides an anticancer composition comprising a diaminotrifluoromethylpyridine derivative of the formula (I) or its pharmaceutically acceptable salt, as an active ingredient:

5



(I)

wherein X is a cycloalkylcarbonyl group, a furancarboxyl group or a benzoyl group which may be substituted by a halogen atom, and Y is an alkylsulfonyl group.

Now, the present invention will be described in detail with reference to the preferred embodiments.

The cycloalkylcarbonyl group for X in the diaminotrifluoromethylpyridine derivative of the formula (I) may be one wherein the cycloalkyl moiety has from 5 to 8 carbon atoms, such as cyclopentylcarbonyl, cyclohexylcarbonyl, cycloheptylcarbonyl or cyclooctylcarbonyl. The halogen atom as the substituent on the benzoyl group for X, may be fluorine, chlorine, bromine or iodine. The alkylsulfonyl group for Y may be one wherein the alkyl moiety has from 1 to 18 carbon atoms, such as methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, hexylsulfonyl, heptylsulfonyl, octylsulfonyl, decylsulfonyl or nonadecylsulfonyl, and such an alkyl moiety may be of a straight chain structure or a branched chain structure.

The salt of the diaminotrifluoromethylpyridine derivative may be any salt so long as it is a pharmaceutically acceptable salt. For example, an alkali metal salt such as a potassium salt or a sodium salt, an alkaline earth metal salt such as a calcium salt, or an organic amine salt such as a triethanolamine salt or a tris(hydroxymethyl)aminomethane salt may be mentioned. Among such salts, some may have crystal water.

Specific examples of the diaminotrifluoromethylpyridine derivative of the formula (I) or its salt, include N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexane-carboxamide or its sodium salt, N-(2-isopropylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclopentane-carboxamide, N-(2-methylsulfonylamino-5-trifluoromethyl-3-pyridyl)-2-furancarboxamide, N-(2-methylsulfonylamino-5-trifluoromethyl-3-pyridyl)-4-fluorobenzamide, and N-(2-isopropylsulfonylamino-5-trifluoromethyl-3-pyridyl)-3-fluorobenzamide.

The diaminotrifluoromethylpyridine derivative or its pharmaceutically acceptable salt is useful as an active ingredient of an anticancer composition. Particularly, such a compound has a suppressive effect of carcinogenesis and is effective, for example, for suppressing multiple carcinogenesis after removal of solid tumor. Such multiple carcinogenesis may take place in a case of e.g. superficial bladder cancer, hepatic

cancer or lung cancer, and the compound suppresses relapse of such a cancer after removal of the solid tumor. The relapse process after removal of the solid cancer includes a phenomenon such as invasion or
5 implantation of cancer cells released by the removal to the surrounding tissues (so-called tumor metastasis). Such a compound has been found to have an inhibitory activity against cell adhesion and cell infiltration, as one of its activities. Thus, such a compound is expected
10 to be effective also for suppressing tumor metastasis. Further, such a compound suppresses a progress from colic polypus to colon cancer, or a progress from hyperplasia by papilloma virus to uterine cervix cancer.

To administer the diaminotrifluoromethylpyridine
15 derivative or its salt as an active ingredient of an anticancer composition, it is formulated alone or together with a pharmaceutically acceptable carrier into a drug composition suitable for peroral, or parenteral administration, such as a tablet, a powder, a capsule, a
20 granule, an injection drug, an ointment, an inhalant or a suppository, and it is administered in the form of such a drug formulation.

As a drug formulation suitable for peroral administration, a solid composition such as a tablet, a
25 capsule, a powder, a granule or a troach; or a liquid composition such as a syrup suspension, may be mentioned. The solid composition such as a tablet, a capsule, a

powder, a granule or a troach may contain a binder such as fine crystalline cellulose, gum arabic, tragacanth gum, gelatine or polyvinyl pyrrolidon; an excipient such as starch, lactose or carboxymethyl cellulose; a

5 disintegrator such as arginic acid, corn starch or carboxymethyl cellulose; a lubricant such as magnesium stearate, light silicic anhydride or colloidal silicon dioxide; a sweetener such as sucrose; or a flavoring agent such as peppermint or methyl salicylate. The

10 liquid composition such as a syrup or a suspension may contain sorbitol, gelatine, methyl cellulose, carboxymethyl cellulose, a vegetable oil such as a peanut oil, an emulsifier such as lecithin as well as a

15 sweetener, a preservative, a colorant or a flavoring agent, as the case requires. Such a composition may be provided in the form of a dried formulation. These formulations may contain from 1 to 95% by weight of the active compound.

A drug formulation suitable for parenteral

20 administration may, for example, be an injection drug, an inhalant, an ointment or a suppository. The injection drug may be prepared by dissolving the compound in the form of a salt in usual water for injection, or may be formulated into a formulation suitable for injection such

25 as a suspension or an emulsion (in a mixture with a pharmaceutically acceptable oil or liquid). In such a case, it may contain benzyl alcohol as an antibacterial

agent, ascorbic acid as an antioxidant, a pharmaceutically acceptable buffer solution or a reagent for adjusting the osmotic pressure. Such an injection drug preferably contains from 0.1 to 50% by weight of the active compound.

The inhalant may be formulated by dissolving the compound of the present invention alone or together with a pharmaceutically acceptable inert carrier in an aerosol or nebulizer solution, or may be administered to the respiratory airway in the form of fine powder for inhalation. In the case of fine powder for inhalation, the particle size is usually not more than 50 μm , preferably not more than 10 μm . Such an inhalant may be used, if necessary, in combination with other antiasthmatic agent or bronchodilator.

An ointment may be prepared by a conventional method by an addition of a commonly employed base or the like. The ointment may contain from 0.1 to 30% by weight of the active compound.

The suppository may contain a carrier for formulation, such as polyethylene glycol, lanolin, cacao butter or fatty acid triglyceride. The suppository may contain from 1 to 95% by weight of the active compound.

The above-mentioned drug compositions suitable for peroral or parenteral administration, may be formulated by conventional methods so that after administration to a patient, the active component will be rapidly discharged,

gradually discharged or belatedly discharged.

The dose of the active ingredient varies depending upon the type of the compound, the administration method, the condition of the patient or the animal to be treated.

5 The optimum dose and the number of administration under a specific condition must be determined by the judgment of a competent doctor. Usually, however, a daily dose to an adult is from about 0.1 mg to about 10 g, preferably from about 1 mg to about 1 g. In the case of the above

10 inhalation method, the dose of the compound of the present invention is preferably from about 0.01 mg to about 1 g per administration.

Now, specific Formulation Examples of the anticancer composition of the present invention will be given.

15 FORMULATION EXAMPLE 1. (tablet)

(1) Active ingredient	20 mg
(2) Lactose	150 mg
(3) Starch	30 mg
(4) Magnesium stearate	6 mg

20 The above composition is tabletted so that the components (1) to (4) constitute one tablet.

FORMULATION EXAMPLE 2 (powder, microgranule or granule)

(1) Active ingredient	20 mg
(2) Sugar ester	180 mg
25 (3) Surfactant	15 mg
(4) Light silicic anhydride	25 mg

The components (1) to (4) are mixed to obtain a

powder drug. Then, the mixture is granulated to obtain a microgranule or granule.

Such a powder, microgranule or granule may be sealed in a capsule to obtain a capsule drug.

5 FORMULATION EXAMPLE 3 (hard gelatine capsule)

(1) Active ingredient	25 mg
(2) Starch	200 mg
(3) Magnesium stearate	10 mg

The components (1) to (3) are packed in a hard
10 gelatine capsule to obtain a hard gelatine capsule drug.

FORMULATION EXAMPLE 4 (injection drug)

(1) Active ingredient	1 mg
(2) D-mannitol	10 mg
(3) Tris(hydroxymethyl)aminomethane	2.16 mg

15 A tris buffer containing the components (1) to (3) is freeze-dried to obtain an injection drug.

FORMULATION EXAMPLE 5 (ointment for external skin application)

(1) Active ingredient	0.5 g
20 (2) White vaseline	25 g
(3) Stearyl alcohol	22 g
(4) Propylene glycol	12 g
(5) Sodium lauryl sulfate	1.5 g
(6) Ethyl para-hydroxybenzoate	0.025 g
25 (7) Propyl para-hydroxybenzoate	0.015 g
(8) Purified water	100 g

The components (1) to (8) are formulated into an

ointment for external skin application by a usual method for preparation of an ointment.

BEST MODE FOR CARRYING OUT THE INVENTION

TEST EXAMPLE 1

5 Suppressive effect of carcinogenesis against BOP-induced biliary tract cancer of hamster

The common duct for the bile duct and the pancreatic duct of a female Syrian golden hamster of five weeks old was subjected to ligature ablation, followed by
10 cholecystoduodenostomy, to obtain an experimental model in which pancreatic fluid flowed backward into the biliary tract. From one week after the operation, N-nitrosobis(2-oxopropyl)amine (carcinogen BOP) was subcutaneously administered in an amount of 10 mg/kg once
15 every week for ten weeks, and the hamster was fed the normal diet for 16 weeks (control group).

To a test group, 200 ppm of sodium salt of N-(2-ethylsulfonylamino-5-trifluoromethyl-3-pyridyl)cyclohexane carboxamide was administered as mixed
20 with the normal diet for 16 weeks.

After termination of feeding period, histopathological examination of the gallbladder and the bile duct was carried out. The results are shown in Table 1.

Table 1


	Control group	Test group
n	19	9
Gallbladder cancer	15 (78.9%)	3 (33.3%)
Bile duct cancer	7 (36.8%)	0 (0%)

In the control group (n=19), biliary tract cancer resulted in a high ratio i.e. gallbladder cancer: 78.9% and bile duct cancer: 36.8%. Whereas, in the test group (n=9), formation of biliary tract cancer was suppressed as compared with the control group to a level of gallbladder cancer: 33.3% and bile duct cancer: 0%.

From the histopathological type, in the control group, tubular adenocarcinoma constituted 25.6%, while in the test group, each was papillary adenocarcinoma, and transfer to anaplastic type was found to be suppressed as compared with the control group.


CLAIMS

1. An anticancer composition comprising a
diaminotrifluoromethylpyridine derivative of the formula
(I) or its pharmaceutically acceptable salt, as an active
5 ingredient:



- wherein X is a cycloalkylcarbonyl group, a furancarboxyl
10 group or a benzoyl group which may be substituted by a
halogen atom, and Y is an alkylsulfonyl group.
2. The anticancer composition according to Claim 1,
wherein the diaminotrifluoromethyl pyridine derivative is
N-(2-ethylsulfonylamino-5-trifluoromethyl-3-
15 pyridyl)cyclohexane-carboxamide, N-(2-
isopropylsulfonylamino-5-trifluoromethyl-3-
pyridyl)cyclopentane-carboxamide, N-(2-
methylsulfonylamino-5-trifluoromethyl-3-pyridyl)-2-
furancarboxamide, N-(2-methylsulfonylamino-5-
20 trifluoromethyl-3-pyridyl)-4-fluorobenzamide or N-(2-
isopropylsulfonylamino-5-trifluoromethyl-3-pyridyl)-3-
fluorobenzamide.
3. An anticancer composition comprising N-(2-
ethylsulfonylamino-5-trifluoromethyl-3-
25 pyridyl)cyclohexane-carboxamide or its sodium salt, as an
active ingredient.
4. Use of a diaminotrifluoromethylpyridine derivative of

the formula (I) or its pharmaceutically acceptable salt,
as an active ingredient of an anticancer composition:



5

wherein X is a cycloalkylcarbonyl group, a furancarboxyl group or a benzoyl group which may be substituted by a halogen atom, and Y is an alkylsulfonyl group.

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/JP 98/00776

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 465 913 A (ISHIHARA MINING & CHEMICAL CO) 15 January 1992 cited in the application see abstract	1-3
Y	see page 51, line 24 - line 39; tables 5-7 see page 70, line 54 - page 72, line 45; claims	4
X	--- H. KIMURA ET AL.: "SYNTHESIS AND ANTIPANCREATITIS ACTIVITIES OF NOVEL N-(2-SULFONYLAMINO-5-TRIFLUOROMETHYL-3-PYR IDYL)CARBOXAMIDE DERIVATIVES AS PHOSPHOLIPASE A2 INHIBITORS" CHEM. PHARM. BULL., vol. 43, no. 10, 1995, pages 1696-1700, XP002070541	1-3
Y	see the whole document --- -/--	4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 July 1998

Date of mailing of the international search report

20/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/JP 98/00776

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	M.R. STEINER ET AL.: "INHIBITORS OF PHOSPHOLIPASE A2 AND EICOSANOID BIOSYNTHESIS IN CANCER" DRUG NEWS & PERSPECTIVES, vol. 7, no. 6, 1994, pages 344-351, XP002070542 see the whole document	4
Y	M. SNOJ: "METASTATIC INTRAPERITONEAL SPREAD IS INITIATED BY PHOSPHOLIPASE A2" MEDICAL HYPOTHESES, vol. 44, no. 5, 1995, pages 392-394, XP002070543 see the whole document	4

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/JP 98/00776

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0465913 A	15-01-1992	JP 5170742 A	09-07-1993
		AT 157969 T	15-09-1997
		AU 642267 B	14-10-1993
		AU 7949791 A	16-01-1992
		CA 2045857 A,C	11-01-1992
		CN 1058396 A,B	05-02-1992
		DE 69127595 D	16-10-1997
		DE 69127595 T	22-01-1998
		DK 465913 T	20-10-1997
		ES 2107434 T	01-12-1997
		IL 98762 A	26-05-1995
		JP 10152473 A	09-06-1998
		JP 6247934 A	06-09-1994
		JP 2762323 B	04-06-1998
		JP 6263735 A	20-09-1994
		RU 2057123 C	27-03-1996
		US 5348967 A	20-09-1994
		US 5492908 A	20-02-1996
		US 5229403 A	20-07-1993
		US 5260320 A	09-11-1993